Jianting Long
- Cancer Research top 5%
- MicroRNA in disease regulation 10
- Cancer-related molecular mechanisms research 7
- Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis 7
- Molecular Biology top 10%
- Circular RNAs in diseases 6
- RNA modifications and cancer 5
- RNA Interference and Gene Delivery 4
- PI3K/AKT/mTOR signaling in cancer 4
- Oncology top 10%
- Biomaterials top 10%
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 5
- Partner nations
- ChinaUnited StatesSwitzerland
In The Last Decade
Jianting Long
50 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 101
- Cancer Research 512
- Hepatology 96
- Molecular Biology 784
- Oncology 290
- Biomaterials 99
Countries citing papers authored by Jianting Long
This map shows the geographic impact of Jianting Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianting Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianting Long more than expected).
Fields of papers citing papers by Jianting Long
This network shows the impact of papers produced by Jianting Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianting Long. The network helps show where Jianting Long may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jianting Long, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 2 | |
| 4 | 2023 | 31 | |
| 5 | miR-500a-3p is a Potential Prognostic Biomarker in Hepatocellular Carcinoma | 2022 | 4 |
| 6 | 2022 | 138 | |
| 7 | 2022 | 2 | |
| 8 | 2020 | 6 | |
| 9 | 2019 | 36 | |
| 10 | 2018 | 20 | |
| 11 | 2018 | 9 | |
| 12 | 2017 | 48 | |
| 13 | 2017 | 6 | |
| 14 | 2015 | 16 | |
| 15 | 2015 | 53 | |
| 16 | 2013 | 15 | |
| 17 | 2013 | 11 | |
| 18 | 2013 | 23 | |
| 19 | 2013 | 5 | |
| 20 | 2013 | 83 |
About Jianting Long
Jianting Long is a scholar working on Cancer Research, Hepatology and Oncology, having authored 51 papers that have together received 1.2k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (10 papers), Cancer-related molecular mechanisms research (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Circular RNAs in diseases (6 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers), RNA modifications and cancer (5 papers), RNA Interference and Gene Delivery (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). The work is most often cited by research in Cancer Research (512 citations), Hepatology (96 citations) and Molecular Biology (784 citations). Jianting Long has collaborated with scholars based in China, United States and Switzerland. Frequent co-authors include Heping Li, Qiangsheng Dai, Baoxian Liu, Chunlin Jiang, Fang Shi, Ming Kuang, Ruifang Zeng, Xiaoyan Xie, Shi Fang and Meihua Qu. Their work appears in journals such as BMC Cancer, Tumor Biology, OncoTargets and Therapy, Oncotarget and Journal of Experimental & Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.